192 related articles for article (PubMed ID: 24967920)
1. [Economic health technology assessment: challenges and perspectives].
Zerda A
Biomedica; 2014; 34(2):161-3. PubMed ID: 24967920
[No Abstract] [Full Text] [Related]
2. A national technology assessment institute.
Howell A
Healthplan; 2003; 44(5):40-5. PubMed ID: 14556611
[No Abstract] [Full Text] [Related]
3. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation for pharmaceuticals in Germany.
Jönsson B
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
[No Abstract] [Full Text] [Related]
5. A furore too far: the widespread disquiet undermining NICE.
Carlisle D
Health Serv J; 2006 Jun; 116(6011):14-5. PubMed ID: 16827515
[No Abstract] [Full Text] [Related]
6. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
[TBL] [Abstract][Full Text] [Related]
7. Technology assessment in the German context.
Drummond M
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
[No Abstract] [Full Text] [Related]
8. Patients' views of explicit rationing: what are the implications for health service decision-making?
Devlin N; Appleby J; Parkin D
J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
[TBL] [Abstract][Full Text] [Related]
9. Health services technology: Part 2, Policy and managerial considerations.
Darr K
Hosp Top; 1998; 76(4):25-30. PubMed ID: 10538910
[No Abstract] [Full Text] [Related]
10. Premier unveils venture. Vendor-sponsored institute to push new technologies.
Hensley S
Mod Healthc; 1998 Feb; 28(6):14. PubMed ID: 10176650
[No Abstract] [Full Text] [Related]
11. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
Taylor R
Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
[TBL] [Abstract][Full Text] [Related]
12. NICE's use of cost effectiveness as an exemplar of a deliberative process.
Culyer AJ
Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
[TBL] [Abstract][Full Text] [Related]
13. Values and evidence colliding: health technology assessment in child health.
Ungar WJ; Prosser LA; Burnett HF
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):417-9. PubMed ID: 23977967
[No Abstract] [Full Text] [Related]
14. Challenges ahead for federal technology assessment.
Neumann PJ
Health Aff (Millwood); 2007; 26(2):w150-2. PubMed ID: 17259197
[TBL] [Abstract][Full Text] [Related]
15. Health technology assessment in Canada: diversity and evolution.
Hailey DM
Med J Aust; 2007 Sep; 187(5):286-8. PubMed ID: 17767434
[TBL] [Abstract][Full Text] [Related]
16. A primer on the assessment of medical technologies.
Matuszewski KA
Pharm Pract Manag Q; 1997 Jan; 16(4):53-65. PubMed ID: 10164160
[TBL] [Abstract][Full Text] [Related]
17. Health technology assessment and policy decisions on hyperbaric oxygen treatment.
Mitton C; Hailey D
Int J Technol Assess Health Care; 1999; 15(4):661-70. PubMed ID: 10645107
[TBL] [Abstract][Full Text] [Related]
18. Technology assessment in healthcare: a review and description of a "best practice" technology assessment process.
Fernandez AM; Schrogie JJ; Wilson WW; Nash DB
Best Pract Benchmarking Healthc; 1997; 2(6):240-53. PubMed ID: 9543920
[TBL] [Abstract][Full Text] [Related]
19. Health technology assessment: research trends and future priorities in Europe.
Nielsen CP; Funch TM; Kristensen FB
J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
[TBL] [Abstract][Full Text] [Related]
20. Challenges for the National Institute for Clinical Excellence.
Maynard A; Bloor K; Freemantle N
BMJ; 2004 Jul; 329(7459):227-9. PubMed ID: 15271837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
